Please login to the form below

Not currently logged in
Email:
Password:

Eli Lily

This page shows the latest Eli Lily news and features for those working in and with pharma, biotech and healthcare.

Nine positive opinions for new drugs at CHMP meeting

Nine positive opinions for new drugs at CHMP meeting

Another medicine for lung cancer, Portrazza (necitumumab) from Eli Lilly, was also backed by the CHMP for the treatment of squamous NSCLC.

Latest news

  • Building brand strength – Part 1 Building brand strength – Part 1

    We have seen products such as Viagra, Prilosec and Lipitor along with some corporate names (eg, Eli Lily, Pfizer and Merck) nominated in our Iconic Brands survey.

  • Positive phase IV results for Zyvox

    Data from the study showed that Zyvox achieved a statistically significantly higher clinical success rate compared with vancomycin, which was first marketed as vancomycin hydrochloride by Eli Lily under the trade

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Both analysts and academics had been getting excited about the Expedition 3 trial of Eli Lilly’s solanezumab, which has been developed to target amyloid-beta - the protein that clumps together

  • Who tops the pharma list? Who tops the pharma list?

    For example, patents for Seroquel (AstraZeneca - 2011 revenues of $5.8bn), Zyprexa (Eli Lily - $4.6bn) and Concerta (J&J - $1.3bn) had all expired by May 2012.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    In July 2012, Eli Lilly opened a diabetes research centre in Shanghai. ... These include GSK's alliance with Binnopharm in Russia, Roche's partnership with Encure Pharmaceuticals to develop affordable versions of Herceptin and MabThera in India, and Eli

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics